793 related articles for article (PubMed ID: 9042270)
21. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
[TBL] [Abstract][Full Text] [Related]
22. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
23. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
24. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
[TBL] [Abstract][Full Text] [Related]
25. [Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion].
Sone S; Yanagawa H; Nii A; Ozaki T; Ogura T
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1434-40. PubMed ID: 1434216
[TBL] [Abstract][Full Text] [Related]
26. [In vitro induction of cytotoxic activity against carcinomatous pleural or peritoneal lymphoid cells cultivated with cytokines, and an immunological phenotypic analysis of the effector cells].
Ebihara T; Koyama S
Gan No Rinsho; 1990 Apr; 36(5):604-10. PubMed ID: 2325266
[TBL] [Abstract][Full Text] [Related]
27. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
[TBL] [Abstract][Full Text] [Related]
28. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
Liu X
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
30. Flow cytometric quantitation of natural killer cells and T lymphocytes expressing T-cell receptors alpha/beta and gamma/delta is not helpful in distinguishing benign from malignant body cavity effusions.
Cornfield DB; Gheith SM
Cytometry B Clin Cytom; 2009 May; 76(3):213-7. PubMed ID: 18803280
[TBL] [Abstract][Full Text] [Related]
31. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.
Dong HP; Elstrand MB; Holth A; Silins I; Berner A; Trope CG; Davidson B; Risberg B
Am J Clin Pathol; 2006 Mar; 125(3):451-8. PubMed ID: 16613351
[TBL] [Abstract][Full Text] [Related]
32. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
33. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
[TBL] [Abstract][Full Text] [Related]
34. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432.
Uchida A; Micksche M
J Natl Cancer Inst; 1983 Oct; 71(4):673-80. PubMed ID: 6413742
[TBL] [Abstract][Full Text] [Related]
35. [Local administration of recombinant interferon-beta to patients with cancer-associated body cavity fluids].
Tanaka N; Terasawa A; Matsui T; Yamada J; Hizuta A; Ichikawa J; Nakayama F; Matsuda T; Orita K
Gan To Kagaku Ryoho; 1988 Feb; 15(2):237-41. PubMed ID: 3341785
[TBL] [Abstract][Full Text] [Related]
36. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
37. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
38. The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis.
van de Molengraft FJ; Vooijs GP
Acta Cytol; 1988; 32(2):183-7. PubMed ID: 3348059
[TBL] [Abstract][Full Text] [Related]
39. Survival of patients with malignancy-associated effusions.
van de Molengraft FJ; Vooijs GP
Acta Cytol; 1989; 33(6):911-6. PubMed ID: 2588923
[TBL] [Abstract][Full Text] [Related]
40. Augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes by the streptococcal preparation OK432.
Uchida A
Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):81-4. PubMed ID: 2423823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
